BillionToOne, Inc. Class A Common Stock (BLLN)vsDanaher Corporation (DHR)
BLLN
BillionToOne, Inc. Class A Common Stock
$97.19
-7.08%
HEALTHCARE · Cap: $4.52B
DHR
Danaher Corporation
$184.30
-0.38%
HEALTHCARE · Cap: $117.48B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 6889% more annual revenue ($24.78B vs $354.54M). DHR leads profitability with a 14.9% profit margin vs 7.0%. DHR trades at a lower P/E of 32.2x. DHR earns a higher WallStSmart Score of 58/100 (C).
BLLN
Hold40
out of 100
Grade: F
DHR
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BLLN.
Margin of Safety
-60.8%
Fair Value
$114.63
Current Price
$184.30
$69.67 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 83.8% year-over-year
Conservative balance sheet, low leverage
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Generating 1.1B in free cash flow
Areas to Watch
Trading at 8.8x book value
0.0% earnings growth
ROE of 5.0% — below average capital efficiency
7.0% margin — thin
Premium valuation, high expectations priced in
3.7% revenue growth
ROE of 7.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BLLN
The strongest argument for BLLN centers on Revenue Growth, Debt/Equity. Revenue growth of 83.8% demonstrates continued momentum.
Bull Case : DHR
The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : BLLN
The primary concerns for BLLN are Price/Book, EPS Growth, Return on Equity. A P/E of 182.2x leaves little room for execution misses.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.
Key Dynamics to Monitor
BLLN profiles as a hypergrowth stock while DHR is a value play — different risk/reward profiles.
BLLN is growing revenue faster at 83.8% — sustainability is the question.
DHR generates stronger free cash flow (1.1B), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
DHR scores higher overall (58/100 vs 40/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BillionToOne, Inc. Class A Common Stock
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company is headquartered in Menlo Park, California.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?